Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

Healthcare Deal Mistakes: 21 Ways Sellers and Raisers Lose Value

Healthcare sellers lose value in three places:

The 21 mistakes below are grouped by deal stage. Each one comes with its cost and its fix. Mistakes 19 to 21 cover owners who raise minority capital instead of selling control.

Data as of November 20, 2026. Each figure names its source, population and date.

The 21 Mistakes, Their Cost and the Fix

# Mistake What it costs Fix
1 No sell-side QoE before launch The buyer's QoE resets EBITDA after the LOI, and the price falls with it Run a sell-side QoE before the first buyer call
2 Unsupported add-backs Each rejected dollar costs the dollar times the multiple Tie every add-back to a source record
3 Real estate mixed into the operating company Comps that don't match and the wrong rent after closing Split OpCo and PropCo and set a market lease
4 No coding and billing audit A lower price or a special indemnity Commission a third-party coding audit
5 Payer contracts not reviewed for assignment and change of control Revenue the buyer discounts, escrows or makes a closing condition Read every major payer contract before launch
6 Data room built after the LOI Slow diligence, a tired buyer, a retrade Build the data room before launch
7 Pricing off headlines or the wrong comp set An asking price several turns too high Match the earnings basis, size band and population
8 Taking add-on pricing for a platform-grade asset 4 to 8 turns by specialty, narrower in dental (Sikich, Q3 2026) Test platform interest first
9 Selling from weakness Median 0.15x revenue in Buckhead FMV's distressed sales, Jan 2023 to Oct 2026 Sell after a growth year
10 One-buyer process No competition on price Run a controlled, competitive process
11 Negotiating headline price instead of cash at close A surprise at the closing table Model net proceeds before signing the LOI
12 Ignoring tax structure Double tax, gain taxed at ordinary rates, tax on rollover with no cash Set entity form, allocation and rollover terms before the LOI
13 Skipping RWI Average total escrow of 14.7% vs 5.1% (SRS Acquiom, 2025 deals) Get an RWI quote during the LOI stage
14 Exclusive LOI with open terms Retrade during exclusivity Fix the peg, escrow, rollover and earnout in the LOI
15 Earnout on metrics the buyer controls The earnout pays little or nothing Use revenue-based targets and operating covenants
16 Rolling equity without diligence A second bite smaller than modeled Check the holdco cap table and preferences
17 Compensation, leases or directorships that track referrals Legal exposure that can reduce price or stall the deal Market-rate terms in signed agreements, reviewed by a healthcare attorney
18 Ignoring corporate practice and transaction notice rules A delayed close or a forced restructuring Map ownership structure and filings at the start
19 Investor returns that track referrals Legal exposure and a raise that may have to be unwound Have a healthcare attorney review the investment structure before marketing it
20 Pricing a minority raise off control-deal comps A valuation investors will not accept Price the minority stake on its own terms
21 No defined exit path for investors Investors pass or tighten terms Write exit rights and timing into the term sheet

Readiness Timeline: When Each Fix Has to Happen

Most of these mistakes are timing failures. Each fix is cheap at the right stage and expensive one stage later.

When Work to finish Mistakes it prevents
12 to 18 months before launch Clean up compensation, lease and directorship agreements. Separate real estate. Fix coding gaps. Start the growth year you will sell on 3, 4, 9, 17
6 to 9 months before launch Sell-side QoE. Add-back support file. Payer contract schedule. Tax structure review with your CPA and tax counsel 1, 2, 5, 12
3 months before launch Data room built. Net proceeds model. Comp set matched to your size band. Buyer list across sponsors, strategics and health systems 6, 7, 8, 10, 11
LOI stage RWI quote. Peg, escrow, rollover, earnout and tax structure fixed in writing. Holdco terms reviewed 13, 14, 15, 16
Before signing Transaction review timing and ownership structure confirmed with your attorney 18

Mistakes 1 to 6: What Buyer Diligence Will Find

The buyer's QoE firm rebuilds your EBITDA line by line. Anything it cannot verify comes out of the number the multiple is applied to.

  1. No sell-side QoE. Sellers who skip it learn their real EBITDA during exclusivity, when they have the least leverage. The Quality of Earnings Prep Checklist lists the schedules buyers test.
  2. Unsupported add-backs. In physician practices, the largest add-back is usually owner compensation normalization. A departing owner-physician has to be replaced at market pay, and the buyer will price that replacement. One-time expenses need invoices. Discretionary spending needs a ledger trail.
  3. Real estate inside the operating company. Buckhead FMV studied 187 U.S. healthcare services control transactions, announced January 2023 through October 2026. Its methodology notes that disclosed prices include real estate in some deals and exclude it in others. If you benchmark against a comp that bundled the building, you overstate your own value. Separate the property and sign a market-rate lease. Then sell or finance the real estate as its own asset.
  4. No coding and billing audit. Sikich's Q3 2026 healthcare M&A update reports fewer home health and hospice closings in 2026. Buyers are discounting billing and compliance risk, and small agencies typically trade at mid-single-digit EBITDA multiples. The same logic applies to every business that depends on reimbursement. Overpayment findings become price cuts or special indemnities.
  5. Payer contracts nobody read. Commercial payer agreements commonly restrict assignment or call for consent or notice on a change of control. In an asset deal, each contract has to be assigned. A payer that withholds consent or asks for re-credentialing interrupts collections after closing. Buyers will also check how Medicare and Medicaid enrollment carries over to the new owner. Buyers treat revenue they cannot confirm will transfer as risk. They price that risk through a lower multiple, a holdback or a closing condition. Before launch, build a schedule of every payer contract with its assignment clause, notice period and termination rights.
  6. Late data room. Build the folder structure before launch. The Healthcare Data Room Checklist sets the order buyers expect.

Add-back defense file. Buyers accept an add-back when it has these four things. Assemble them for each one.

Add-back type Evidence the buyer's QoE will ask for
Owner compensation normalization Market compensation survey for the replacement role, the signed post-close employment agreement, and a production and collections history
One-time legal, consulting or recruiting Invoices, engagement letters, and proof the expense will not recur
Discretionary owner spending General ledger detail tied to card statements
Pro forma rent change The signed or agreed lease at market rate, supported by a rent appraisal
Run-rate revenue from a new provider or site Monthly collections since start, payer mix, and the provider's signed agreement

Mistakes 7 to 10: Anchoring to the Wrong Price

7. Pricing off headlines or the wrong comp set. Bain & Company's Global Healthcare Private Equity Report 2026 puts global healthcare PE deal value at a record estimated $191 billion in 2025. Provider and related services rose 57% to an estimated $62 billion. Bain's 2025 figures use actual data through November 30, 2025, annualized for the rest of the year. Those numbers say little about a practice with $3 million of EBITDA. FOCUS Investment Banking's 2026 dashboard found that fewer than ten large deals produced roughly 70% of 2025 healthcare transaction value. The same dashboard attributes roughly 68% of Q2 2025 enterprise value growth among public healthcare operators to higher multiples, not higher EBITDA. Public multiples move on sentiment. Private practice multiples move on size.

The right comp matches three things: your earnings basis, your size band, and the population the data came from. PitchBook data reported by Sikich shows the median healthcare M&A multiple falling from 14.5x EV/EBITDA in 2024 to 13x in 2025, then 11.6x for 2026 year to date as of Sikich's Q3 2026 update. Per the same source, the median PE-backed healthcare services target in 2025 sold at 13.6x on implied EBITDA of roughly $33 million. A practice with $3 million of EBITDA is not that company.

The deal mix can move a median as much as the market does. Buckhead's median EBITDA multiple ran 11.4x in 2023, 9.7x in 2024, 6.5x in 2025 and 9.1x in 2026 through October. Buckhead attributes the 2025 dip to a smaller, more mid-market mix of deals, not a broad repricing.

Dataset Population and period Band defined by Band Median or range
Axia Growth Closed healthcare-sector small-business sales with a sale price over $500K, from Axia's database of 4,554 closed sales, as of Oct 28, 2026. The $500K floor is on sale price, so SDE bands can sit below it SDE Under $500K (n=182) 3.4x SDE (p25 to p75: 2.7x to 4.2x)
Axia Growth Same SDE $1M to $2M (n=22) 3.3x SDE (2.7x to 7.5x), small sample
Sikich Physician practices, indicative ranges, Q3 2026 update EBITDA Under $1M 5 to 7x EBITDA
Sikich Same EBITDA $1M to $3M 7 to 9x EBITDA
Sikich Same EBITDA $3M to $5M 9 to 11x EBITDA
Sikich Same EBITDA Above $5M 11 to 13x EBITDA
Axia Growth Closed healthcare-sector sales, as of Oct 28, 2026 EBITDA $10M+ (n=17) 12.9x EBITDA (9.4x to 18.5x)
Buckhead FMV U.S. healthcare services control deals with disclosed prices, Jan 2023 to Oct 2026 Transaction value Below $10M 2.8x EBITDA, 0.27x revenue
Buckhead FMV Same Transaction value Above $200M 11.2x EBITDA, 1.34x revenue

Table sources: Axia Growth closed-sales data as of Oct 28, 2026, Sikich's Q3 2026 update, and Buckhead FMV's January 2023 to October 2026 control-deal dataset, each linked in the first row where it appears. The Axia $1M to $2M band rests on only 22 sales. Its 2.7x to 7.5x interquartile spread means the 3.3x median is weak evidence on its own.

See the healthcare multiples by segment and size chart.

Buckhead's 2.8x for deals under $10 million and Sikich's 5 to 7x for practices under $1 million of EBITDA measure different things.

Both can be true at once. A practice with $800,000 of EBITDA that sells at 6x is a $4.8 million deal, which falls inside Buckhead's under-$10 million cell (our arithmetic). For a going-concern practice sale, use the EBITDA-banded ranges.

Small sales are priced on seller's discretionary earnings (SDE), which add back one owner's full compensation. If you apply an EBITDA multiple to SDE, you capitalize that compensation as if it were profit. The buyer still has to pay someone to do the owner's work.

Segment matters as much as size. Buckhead FMV's January 2023 to October 2026 dataset reports segment medians of 12.4x EBITDA for ASCs, 11.6x for outsourced services and 9.5x for hospitals. Sikich, citing PitchBook, puts the 2025 median ASC multiple at 7.9x and calls it the highest in at least eight years. That is well below the 13x median the same source gives for all healthcare M&A in 2025, which suggests PitchBook's ASC figure covers a different, likely smaller, deal population. Sikich does not describe that population, so treat 7.9x as a directional ASC reference, not a precise comp.

The 4.5-turn gap between those ASC figures (our arithmetic) comes from two different populations, not from disagreement. Buckhead's EBITDA medians rest on the 68 deals with positive disclosed EBITDA. Its methodology states that large and public-company deals disclose EBITDA far more often, so those medians lean toward larger transactions. Use the source whose population matches your size.

Revenue multiples spread even wider. Damodaran's January 2026 EV/sales data for U.S. public companies shows healthcare support services (104 firms) at 0.46x and healthcare IT (115 firms) at 5.31x. See Healthcare Valuation Multiples by Sector and Specialty for the full table.

8. Taking add-on pricing for a platform-grade asset. PESP data reported by Becker's ASC Review counts 148 outpatient care deals in 2025, of which 119 were add-ons. Dermatology led with 24 deals, eye care had 22 and oncology had 9. PESP notes its final count is likely an underestimate. Most sellers are add-ons.

Sikich's Q3 2026 update reports that platforms command a four- to eight-turn premium over add-on practices by specialty. Dental sits below that range. Sikich puts dental platforms at 9 to 11x and add-ons at 5 to 8x. That is a 3.5-turn gap at the midpoints and 1 to 6 turns across the ranges (our arithmetic).

Bain's 2026 physician group research shows what sponsors now pay for in a platform. One is operational efficiency through AI and analytics. The other is readiness for value-based care, where orthopedics and cardiology lead through bundled payments.

Signal Platform candidate Likely add-on
EBITDA (Sikich size bands) Above $5M Below $1M
Management COO or CFO who is not a practicing owner Owner-physicians run operations
Footprint Several sites, room to expand into new markets One or two sites
Systems One EHR, central billing, monthly reporting Mixed systems, outsourced or manual billing
Payer position Value-based or bundled contracts in place or in negotiation Fee-for-service only

Our rule of thumb from that table: a group that matches most of the left column should test platform demand before it takes an add-on bid.

9. Selling from weakness. In Buckhead's January 2023 to October 2026 dataset, the 22 distressed sales with reported revenue traded at a median 0.15x revenue. Buckhead says most of them were hospitals sold out of the Steward, Prospect and other bankruptcies. Without distressed sales, the dataset's median rises to 0.98x revenue. Sell after a growth year. If you lost a contract or a key physician, put a recovery quarter on the books before launch.

10. Running a one-buyer process. With a single local hospital bidder, that hospital sets the price. Buckhead found that hospital purchases of individual primary care practices, largely in West Virginia, cluster at 0.05x to 0.15x revenue. That pricing reflects equipment and records, not goodwill.

Hospital buyers are also under margin pressure. Kaufman Hall's Q3 2026 M&A Quarterly Activity Report release (Oct 13, 2026) puts the year-to-date hospital operating margin at 2.5% including allocations, as of August 2026. Nearly 43% of hospitals were operating at a loss. Hospital M&A itself has picked up. Kaufman Hall data reported by Becker's Hospital Review counts 56 hospital transactions announced through Q3 2026, against 46 in all of 2025, the lowest annual count since tracking began in 2011.

The buyer universe is wider than the local system. PAI-Avalere data reported by Axia Growth shows corporate entities owned 33.2% of U.S. physician practices as of January 1, 2026, ahead of hospitals at 30.6%. Competition among sponsors, corporate owners and health systems creates price tension. The Healthcare M&A Process guide covers the sequence.

See the healthcare M&A timeline chart.

Mistakes 11 to 16: Structure, Tax and LOI Terms

11. Negotiating headline price instead of cash at close. Start with enterprise value. Subtract debt, rollover, escrow, fees and the working capital adjustment. What remains reaches the seller's account, and then tax comes out. Run the Deal Proceeds Calculator on every LOI before comparing them.

12. Ignoring tax structure. Two LOIs at the same price can leave the seller with very different after-tax cash. Four decisions drive the difference.

Decision Why it moves after-tax cash Where it is set
Asset or stock sale Buyers generally pay more for assets because they can deduct the price over time. In a C corporation, an asset sale can tax the same gain twice Entity type and LOI
Tax elections and pre-sale reorganizations Some structures give the buyer asset treatment while the seller sells equity. Whether one fits depends on both the seller's entity and the buyer's Pre-LOI planning
Purchase price allocation Price assigned to depreciated equipment can be taxed at ordinary rates. Price assigned to goodwill is generally capital gain Purchase agreement schedule
Rollover mechanics Rollover can often be received tax-deferred when it is structured for that. If it is set up as a taxable sale and reinvestment, it is taxed at closing LOI and holdco documents

The tax layer in the worked example below puts a number on the rollover mistake. See Healthcare Deal Structures for detail by entity type.

13. Skipping representations and warranties insurance. SRS Acquiom's 2026 Deal Terms for M&A Escrows splits its 2025 deal data by whether RWI was identified. The data covers deals across industries, not healthcare alone. Every figure is a percentage of transaction value.

SRS Acquiom, 2025 deals With RWI Without RWI
Total escrow, average 5.1% 14.7%
Total escrow, median 2.8% 11.1%
General indemnification escrow, average 2.2% 11.3%
General indemnification escrow, median 0.5% 10.0%
Sellers' general reps survive closing 43% of deals 89% of deals

RWI carries a premium, underwriting fees and a retention. All of them are priced deal by deal, and the parties negotiate who pays. Get the quote while you compare LOIs. After signing, the buyer controls that conversation.

14. Signing an exclusive LOI with open terms. Some LOIs leave the working capital peg, escrow size, rollover terms, tax structure and earnout definitions "to be agreed." That invites a retrade during exclusivity. The LOI and Term Sheet Red Flags checklist lists the terms to lock.

Term Open (retrade risk) Locked
Working capital peg "Normalized level to be agreed" Dollar figure or trailing 12-month average method, stated
Escrow "Customary" Percentage, duration and release schedule
Rollover "Seller to roll a portion" Percentage, holdco entity, class of equity, tax treatment
Earnout "Based on performance" Metric, target, measurement period, payment curve, covenants
Exclusivity Open-ended Fixed days with a defined extension trigger

15. Earnouts on metrics the buyer controls. EBITDA earnouts depend on cost allocations the buyer decides after closing. A hypothetical, using our arithmetic: a $3.0 million earnout pays if year-one EBITDA reaches $3.2 million. The practice produces $3.3 million before allocations. The buyer then charges a $0.4 million management fee, which drops EBITDA to $2.9 million. Under a cliff structure, the seller gets nothing. Revenue or visit-volume targets with operating covenants are harder to manipulate. A sliding payment curve beats a cliff. Do not tie an earnout to referrals into the buyer's facilities (see Mistake 17).

16. Rolling equity without diligence. The value of your rollover depends on the holdco's next sale. The holdco's terms decide how much of that sale reaches you. Senior debt, preferred returns and drag rights all sit ahead of or above rolled common equity. Before you agree to a rollover percentage, check each one with the Physician Rollover Equity Checklist.

Worked Example: $3.5 Million of Claimed EBITDA to Cash at Close

This is a hypothetical, and the arithmetic is ours. A multi-site specialty group markets $3.5 million of adjusted EBITDA. The buyer's QoE rejects $500,000 of add-backs, mostly unsupported owner compensation normalization. The agreed multiple is 10x, inside Sikich's Q3 2026 range of 9 to 11x for practices with $3 million to $5 million of EBITDA.

Assumptions:

Line No RWI With RWI
Claimed EBITDA ($3.5M) × 10x $35.00M $35.00M
QoE-adjusted EBITDA ($3.0M) × 10x = enterprise value $30.00M $30.00M
20% rollover equity ($6.00M) ($6.00M)
Cash consideration $24.00M $24.00M
Debt payoff ($2.00M) ($2.00M)
Escrow (11.1% vs 2.8% of $30.0M) ($3.33M) ($0.84M)
Seller share of RWI cost n/a ($0.10M)
Advisory, legal and QoE fees ($1.20M) ($1.20M)
Cash at close $17.47M $19.86M

The rejected add-backs remove $5.0 million of enterprise value before any term is negotiated. Without RWI, a $35 million headline becomes $17.47 million at close. RWI raises cash at close by a net $2.39 million, from $17.47 million to $19.86 million. The smaller escrow frees $2.49 million ($3.33 million less $0.84 million). Subtract the seller's $0.10 million share of the RWI cost and the net gain is $2.39 million. Escrow is deferred cash, not lost cash. It is released on the purchase agreement's schedule, minus any claims paid.

Tax layer (With RWI case). Assumptions: zero tax basis in the practice and an illustrative 25% blended rate on gain. These are modeling inputs, not any seller's actual rates.

Line Rollover tax-deferred Rollover taxable at close
Cash at close $19.86M $19.86M
Tax on $6.00M rollover at 25% $0 at close ($1.50M)
Cash at close after rollover tax $19.86M $18.36M

Both columns still owe tax on the cash proceeds. The difference is $1.50 million paid at closing on equity that produced no cash and may not be liquid for years. Allocation works the same way. Assume a 40% ordinary rate against the 25% capital gain rate. Then every $1 million of price shifted from goodwill to recaptured equipment costs $150,000 (our arithmetic).

Mistakes 17 and 18: Referral Laws, Corporate Practice and Transaction Filings

17. Compensation, leases or directorships that track referrals. In a sale, the purchase price, post-close compensation, earnouts and rollover returns all go to physicians who may refer to the buyer, and the buyer's counsel will look at whether any of them is tied to referrals. Pay, leases or directorships linked to referrals can create legal exposure. Below-market space leased to referring physicians and directorships with no record of the work done are common diligence findings. Fix them before launch with market-rate terms in signed written agreements. The healthcare compliance due diligence guide lists the questions to ask. Have a healthcare attorney review your arrangements.

18. Ignoring corporate practice and transaction filing rules. In some states, buyers acquire clinical practices through a management services organization, and how that is structured shapes what the seller actually sells. Federal and state transaction reviews can also add time before closing, so build them into the timeline from day one. See Management Services Organizations and healthcare M&A process guide, and take the questions there to your own attorney.

Those filings can also expose your terms. Buckhead FMV built part of its price dataset from state certificate-of-need and transaction-notice filings. Assume competitors and future buyers can read your price.

Mistakes 19 to 21: Raising Minority Capital in a Healthcare Business

A minority recap or growth raise keeps the owner in control. In a healthcare business, it also brings the same regulatory and valuation tests as a sale.

19. Investor returns that track referrals. Physician investors in an ASC, imaging center or lab are often also its referral sources. Any waterfall, bonus pool or special allocation that pays referring physicians more for more cases will be flagged by an institutional investor's counsel, because returns linked to referrals can create legal exposure. Document how each physician's interest was priced, and offer the same terms to referring and non-referring investors. The Raising Capital From Physician Investors and Capital Raising for Healthcare Companies guides cover this area. Have a healthcare attorney review the structure before you market the offering.

20. Pricing a minority raise off control-deal comps. Most published healthcare multiples describe control transactions. Buckhead's dataset covers control deals only and excludes minority and physician-syndication stakes outright.

Right Control buyer Minority investor (unless the documents grant it)
Set strategy and budget Yes No
Replace management Yes No
Choose timing and form of exit Yes No
Receive cash before common equity Through debt and structure Only with a preferred or structured security

A control multiple prices every right in the middle column. Healthtech founders make a related error with public data. Damodaran's 5.31x EV/sales for healthcare IT describes 115 listed U.S. companies in January 2026, not a private company raising its first institutional round. Price the stake on its own terms: projected cash returns, governance rights and the investor's place in the capital stack.

See the healthcare capital stack chart.

21. No defined exit path for investors. A minority investor's return arrives at exit, and the healthcare exit market swings hard. Bain's Global Healthcare Private Equity Report 2026 puts global healthcare PE exit value at an expected $156 billion in 2025, up from $54 billion in 2024. Bain also estimates more than $120 billion of sponsor-to-sponsor deal value in 2025. Exit value nearly tripled in one year (our arithmetic), and it can fall as fast. An offering that leaves the exit open asks the investor to carry that swing alone.

Write these into the term sheet:

Then run reverse due diligence on the investor's own exit record before you sign.

Scoring Two LOIs: Why the Higher Headline Can Pay Less

Sellers who make Mistakes 11 to 16 usually make them while choosing between offers. This hypothetical uses the same group as the worked example, with $3.0 million of QoE-adjusted EBITDA, the same debt and fees, and SRS Acquiom's 2025 median escrows. The arithmetic is ours.

Line LOI A LOI B
Multiple on $3.0M QoE-adjusted EBITDA 11x 10x
Enterprise value $33.00M $30.00M
Rollover equity 30% ($9.90M) 20% ($6.00M)
Cash consideration $23.10M $24.00M
Debt payoff ($2.00M) ($2.00M)
Escrow No RWI, 11.1% ($3.66M) RWI, 2.8% ($0.84M)
Seller share of RWI cost n/a ($0.10M)
Advisory, legal and QoE fees ($1.20M) ($1.20M)
Cash at close $16.24M $19.86M
Working capital peg "To be agreed" Trailing 12-month average method, stated
Earnout EBITDA target, cliff payment None
Exclusivity Open-ended Fixed period with a defined extension trigger
Rollover tax treatment Not addressed Stated as tax-deferred
Holdco terms Not provided Cap table and preferences shared

LOI A is $3.0 million higher on the headline and $3.62 million lower at close. It also puts $3.90 million more of the seller's value into holdco equity, whose worth depends on terms the seller has not seen. Some of the gap narrows over time, because LOI A's larger escrow is deferred cash that comes back minus claims. Every open term in LOI A's lower rows is a point the buyer can reprice during exclusivity.

Before you choose, confirm for each LOI:

Questions Owners Ask

What is the most expensive mistake in a healthcare practice sale?

Overstated EBITDA. Buyers price on adjusted EBITDA times a multiple. Each dollar of add-back that fails the buyer's quality of earnings review costs the seller that dollar times the multiple. At 10x, a $500,000 add-back the buyer rejects removes $5 million of enterprise value (our arithmetic). Run a sell-side QoE before launch. It finds those items while the seller still controls the timing and the story.

How much of the purchase price goes into escrow?

SRS Acquiom's 2025 deal data covers deals across industries. On deals without representations and warranties insurance, total escrow averaged 14.7% of transaction value, with a median of 11.1%. On deals with RWI, the average was 5.1% and the median 2.8%. Escrow is deferred cash. It is released on the schedule the purchase agreement sets, minus any claims paid. Decide on RWI at the LOI stage.

Should a practice sell as an add-on or wait to become a platform?

Most deals are add-ons. In PESP data reported by Becker's ASC Review, 119 of the 148 outpatient care deals in 2025 were add-ons. Sikich's Q3 2026 update reports that platforms trade four to eight turns above add-on practices by specialty. The gap is narrower in dental. Our rule of thumb, built on Sikich's EBITDA size bands: a group above $5 million of EBITDA with a management layer and several sites should test platform interest before accepting add-on pricing. Below $1 million of EBITDA, most groups should expect add-on pricing, though specialty, growth and payer mix can change that.

Does deal structure change what the seller keeps after tax?

Yes, and often by more than the escrow terms do. Three things change the after-tax number: asset or stock form, the purchase price allocation, and whether rollover equity is received tax-deferred. In our worked example, a $6 million rollover set up as a taxable sale costs $1.5 million of tax at closing at an assumed 25% rate. That tax is paid on equity that produced no cash.

What do investors check first in a healthcare minority raise?

Three things. First, how returns reach physician owners who also refer patients, because institutional investors' counsel will test whether those returns track referrals. Second, whether the valuation came from control-deal comps, which price a different asset than a minority stake. Third, how the investor gets out. The exit rights, timing and likely buyers should be written into the term sheet.

Sources